GENE fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
GENE does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company